Form 4 for CTKB Cytek Biosciences, Inc.

Accepted 2021-07-27 00:00:00 ET · period of report 2021-07-22 · accession 0001209191-21-048384 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2021-07-27	2021-07-22	CTKB	Jiang Wenbin	Pres, CEO, Dir	C - Cnv Deriv	—	+2.67M	2.67M	New	—
DI	2021-07-27	2021-07-22	CTKB	Jiang Wenbin	Pres, CEO, Dir	C - Cnv Deriv	$0.00	-2.67M	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-22	C	A	2,666,600	—	2,666,600	I See footnote	—	—	(F1) Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. (F2) These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any.
2	Derivative	Series A Preferred Stock	2021-07-22	C	D	2,666,600	$0.00	0	I See footnote	— · — to —	2,666,600 Common Stock	(F2) These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any. (F1) Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.